Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
  • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/02—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0048—Eye, e.g. artificial tears
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
  • A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
  • A61L12/10—Halogens or compounds thereof
  • A61L12/102—Chlorine dioxide (ClO2)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents

Definitions

• the present invention relates to preserving ophthalmic solutions. More particularly it relates to the use of stabilized chlorine dioxide to preserve ophthalmic solutions.
• contact lenses has become widespread as a replacement for conventional eye glasses because of the improved vision obtained by the wearer or for aesthetic reasons.
• Contact lenses accumulate microorganisms and cellular debris from the eye. Thus, the lenses must be periodically removed and cleaned to prevent irritation of the eye or infection. Solutions used in lens care must be preserved by some means to interdict introducing microbial contaminants onto contact lenses or the eye. Disinfecting preparations are part of the regimen indicated for contact lens care.
• ophthalmic solutions have heretofore been used with lenses.
• the composition of the ophthalmic solution will often be dictated by the polymeric materials employed in the fabrication of the contact lens. Because of the chemical composition of most ophthalmic solutions, the contact lenses cleaned and soaked in such solutions must be rinsed prior to placement in the wearer's eye to prevent irritation of the eye.
• US Patent No. 4,499,077 discloses antimicrobial solutions containing a combination of a quaternary ammonium compound and stabilised chlorine dioxide for treating contact lenses. This document states explicitly that it is not possible to obtain ophthalmically acceptable effective antimicrobial compositions containing chlorine dioxide alone.
• U.S. Patent Nos. 4,696,811 and 4,689,215 disclose the use of stabilized chlorine dioxide for the treatment and prevention of oral disease, the reduction of malodor, as an anti-plaque agent, an anti-gingivitis and anti-periodontitis agent, as well as a denture soak and a contact lens soak. That is, the two before-referenced patents disclose the use of 0.005 percent to 0.02 percent stabilized chlorine dioxide in sterilized water as a contact lens soaking formulation. However, the references are void of any teaching or suggestion that stabilized chlorine dioxide can be incorporated into an aqueous saline ophthalmic solution as a preservative for such a solution.
• the present invention relates to an aqueous ophthalmic solution containing an effective minor amount of stabilized chlorine dioxide to effectively preserve the ophthalmic solution.
• a preserved ophthalmic formulation comprising an ophthalmically acceptable aqueous medium and, included therein, stabilised chlorine dioxide in an amount in a range from 0.0002 to 0.02 weight/volume % effective to act as the sole preservative in said formulation, an ophthalmically acceptable buffer component in an amount effective to maintain said formulation at a pH in a range from 6.8 to 8 and an ophthalmically acceptable inorganic salt in an amount effective to maintain the tonicity of said formulation at an ophthalmically acceptable level.
• the preserved ophthalmic formulations of the invention preferably consist essentially of the ophthalmically acceptable aqueous medium, stabilised chlorine dioxide, ophthalmically acceptable buffer component and said ophthalmically acceptable inorganic salt.
• the present invention relates to an aqueous ophthalmic solution
• an aqueous ophthalmic solution comprising purified water as a vehicle, from about 0.0002 to about 0.02 weight/volume percent stabilized chlorine dioxide as the sole preservative, and an effective minor amount of an ophthalmically acceptable inorganic salt to provide the ophthalmic solution with a tonicity value substantially corresponding to the tonicity value of fluids of an eye.
• the ophthalmic solution also includes an effective minor amount of a buffering agent.
• the pH of the ophthalmic solution can be adjusted, if required, by addition of an acid or a base so that the ophthalmic solution has an acceptable physiological pH (i.e., a pH in the range of from about 6.8 to about 8).
• An object of the present invention is to provide a preservative for ophthalmic solutions.
• Another object of the present invention while achieving the before-stated object, is to provide an ophthalmic solution wherein the solution has a pH and tonicity value substantially corresponding to such values of the fluids of the human eye.
• Another object of the present invention while achieving the before-stated objects, is to provide an aqueous saline ophthalmic solution having incorporated therein a preserving agent such that the integrity of the saline solution is maintained.
• Yet another object of the present invention is to provide an improved composition useful as a disinfectant for ophthalmic devices.
• the incorporation of a preserving amount of stabilized chlorine dioxide into an ophthalmic formulation has been found to be an effective preservative for ophthalmic formulations.
• the preserving amount of stabilized chlorine dioxide incorporated into an ophthalmic formulation can vary widely but will generally be an amount sufficient to reserve the integrity of the formulation.
• stabilized chlorine dioxide is well known in the industry and by those skilled in the art.
• U.S. Patent No. 2,271,242 discloses a form of stabilized chlorine dioxide and a method for producing same which can be used as a preservative for aqueous ophthalmic solutions.
• a commercially available stabilized chlorine dioxide which can be utilized in the practice of the present invention is the proprietary stabilized chlorine dioxide of Bio-Cide International, Inc. of Norman, Oklahoma.
• aqueous ophthalmic solution as used herein is to be understood to mean a solution containing sterilized water as the vehicle and having at least one other component, such as an ophthalmically acceptable inorganic salt, which can be administered to or placed in the eye; and wherein the solution will not possess toxic properties or have a deleterious effect on the tissue of the eye. That is, such solutions will not cause stinging or discomfort, redness or other adverse reactions to the eye under normal use conditions.
• ophthalmically acceptable inorganic salt as used herein is to be understood to mean any inorganic salt which is capable of providing the ophthalmic solution with the desired tonicity values and which does not irritate or cause damage to the tissue of the eye.
• one aspect of the present invention resides in the use of a preserving amount of stabilized chlorine dioxide in aqueous ophthalmic formulations, particularly a saline ophthalmic solution; or as an ingredient in the formulation of an aqueous ophthalmic solution, particularly a saline solution.
• a preserving amount of stabilized chlorine dioxide in aqueous ophthalmic formulations, particularly a saline ophthalmic solution; or as an ingredient in the formulation of an aqueous ophthalmic solution, particularly a saline solution.
• the amount of stabilized chlorine dioxide incorporated in the ophthalmic formulation as a preservative can vary widely provided that such amount effectively prevents microbial growth in the formulation.
• microbial growth in the ophthalmic formulation can be prevented when the amount of stabilized chlorine dioxide introduced into the formulation is from about 0.0002 to about 0.02 weight/volume percent of the solution, desirably from about 0.004 to about 0.01 weight/volume percent.
• the ophthalmic solution In order to insure that the aqueous ophthalmic solution containing a preserving amount of stabilized chlorine dioxide does not irritate one's eye, it is desirable that the ophthalmic solution have a pH value of from about 6.8 to about 8 so that the pH of the ophthalmic solution substantially corresponds to the pH value of the fluids in the eye, or which can be tolerated by the eye without causing any discomfort or irritation.
• an effective minor amount of a buffering agent is incorporated into the ophthalmic solution.
• the effective minor amount of buffering agent employed to buffer the ophthalmic solution at a pH of from about 6.8 to about 8 can vary widely and will depend to a large degree on the particular buffering agent employed, as well as the chemical composition of the ophthalmic solution.
• desirable results have been obtained when the amount of buffering agent incorporated into the aqueous ophthalmic solution to stabilize the solution at the acceptable physiological pH is from about 0.05 to about 1 weight/volume percent of the buffering agent.
• any suitable buffering agent can be employed which is compatible with the other ingredients of the ophthalmic solution, and which does not have deleterious or toxic properties which could harm the eye.
• suitable buffering agents are boric acid, sodium borate, sodium phosphates (including mono, di-and tribasic phosphates, such as sodium phosphate monobasic monohydrate, sodium phosphate dibasic heptahydrate, and mixtures thereof).
• any other suitable buffering agent can be employed to stabilize the pH of the ophthalmic solution so that the ophthalmic solution is provided with an acceptable physiological pH, and the before-mentioned buffering agents are merely examples of such buffering agents.
• buffering agents are well known in the art no further examples of such buffering agents which can be utilized in the ophthalmic solutions of the present invention are believed necessary.
• the pH of the aqueous buffered ophthalmic solution can be adjusted by the addition of an effective amount of either a base or an acid, as the case may be. Any suitable base or acid can be employed to adjust the pH of the aqueous buffered ophthalmic solution which does not provide the ophthalmic solution with toxic or deleterious properties which could harm either ophthalmic devices or the eye.
• An example of a base which can be used to adjust the pH of the aqueous buffered ophthalmic solution is 1 N sodium hydroxide; and an example of an acid which can be used to adjust the pH of the aqueous buffered ophthalmic solution is 1 N hydrochloric acid.
• the integrity of an ophthalmic solution can be enhanced by the incorporation of from about 0.0002 to about 0.02 weight/volume percent stabilized chlorine dioxide. That is, the presence of stabilized chlorine dioxide in an ophthalmic solution greatly enhances the useful or shelf life of the ophthalmic solution.
• stabilized chlorine dioxide and an ophthalmically acceptable inorganic salt or other suitable tonicity imparting agent are admixed with sterile water to provide an ophthalmic solution having a tonicity value substantially corresponding to the tonicity value of fluids of the eye.
• the amount of water employed as the vehicle in the ophthalmic solution will vary depending upon the amount of the stabilized chlorine dioxide and the ophthalmically acceptable inorganic salt and/or other suitable tonicity imparting agents employed in the formulation.
• the amount of ophthalmically acceptable inorganic salt utilized can vary widely provided that the amount of the inorganic salt employed is sufficient to provide the ophthalmic solution with the desired tonicity value. Generally the ophthalmic solution will have the desired tonicity value when the amount of ophthalmically acceptable inorganic salt employed in the formulation of the ophthalmic solution is from about 0.5 to about 0.9 weight/volume percent.
• Typical of such ophthalmically acceptable inorganic salts are alkali metal chlorides and alkaline earth metal chlorides, such as sodium chloride, potassium chloride, calcium chloride and magnesium chloride. Because it is desirable that one not have to remove residual aqueous ophthalmic solution from the contact lenses after the soaking and cleansing procedure prior to use, the pH of the ophthalmic solution should substantially correspond with the pH of the fluids of the eye.
• the pH of the ophthalmic solution can be adjusted by the addition of a base or acid, such as 1 N hydrochloric acid or 1 N sodium hydroxide, so that the solution has an acceptable physiological pH.
• a base or acid such as 1 N hydrochloric acid or 1 N sodium hydroxide
• the borate buffered saline solution had the following composition: Ingredients Percent (Weight/Volume) Sodium Chloride USP 0.85 Boric Acid NF 0.10 Purified Water USP* To 100 ml *Quantity sufficient (Q.S.) to provide 100 ml of solution.
• the pH of the buffered solution was adjusted by the addition of either hydrochloric acid NF or sodium hydroxide NF so that the pH of the saline solution was within the range of from about 7.7 to 7.9.
• the stabilized chlorine dioxide was added to the borate buffered saline solution in the following concentrations: Percent (Weight/Volume) 0.005 0.004 0.003 0.002
• a preserving amount of stabilized chlorine dioxide having a raw material age of 54 months was utilized in one sample; and a similar preserving amount of stabilized chlorine dioxide having a raw material age of 2 months was utilized in a second sample.
• Each of the samples of stabilized chlorine dioxide was the proprietary stabilized chlorine dioxide of Bio-Cide International, Inc. of Norman, Oklahoma, under the trademark Purogene. No aging effect was detected between the two samples and their use as a preservative for borate buffered saline solutions. However, the aged stabilized chlorine dioxide (54 month age) possessed a slightly superior activity against the yeast C. albicans .
• a preservative efficacy test was performed on a borate buffered saline solution having a composition similar to that of Example I wherein 0.005 weight/volume percent stabilized chlorine dioxide was added to the borate buffered solution and the resulting mixture stored for 90 days at 45 degrees Centigrade. At the end of the storage period the sample was examined and it was determined that the stabilized chlorine dioxide was an effective preservative for a borate buffered saline solution.
• borate buffered saline solution containing 0.005 weight/volume percent stabilized chlorine dioxide met the before-mentioned criteria for preservatives.
• a control solution of the borate buffered saline solution which did not contain the stabilized chlorine dioxide present did not meet these USP Efficacy criteria for ophthalmics.
• a 21 day subacute eye toxicity study in rabbits was conducted using a borate buffered saline solution containing 0.005 weight/volume percent stabilized chlorine dioxide.
• the borate buffered saline solution containing the stabilized chlorine dioxide had the following composition: Ingredients Percent (Weight/Volume) Stabilized Chlorine Dioxide 0.005 Sodium Chloride USP 0.85 Boric Acid NF 0.10 Purified Water USP* To 100 ml *Quantity sufficient (Q.S.) to provide 100 ml solution.
• the pH of the above buffered saline solution was adjusted so that the pH of the solution was between 7.7 and 7.9.
• the ocular effects of the buffered saline solution containing 0.005 weight/volume percent stabilized chlorine dioxide were evaluated in rabbit eyes in conjunction with Permalens soft contact lenses.
• Test eye lenses were subjected to daily cleaning, rinsing, and overnight soaking with the borate buffered saline solution containing stabilized chlorine dioxide.
• Control eye lenses were subjected to the same regimen using preserved normal saline solution. Lenses were fit directly to the eye and worn daily for a minimum of eight hours for 21 consecutive days.
• a 1 day acute eye toxicity and cytotoxicity study in rabbits was conducted using a borate buffered saline solution containing 0.005 weight/volume percent stabilized chlorine dioxide.
• the borate buffered saline solution containing the stabilized chlorine dioxide had the following composition: Ingredients Percent (Weight/Volume) Stabilized Chlorine Dioxide 0.005 Sodium Chloride USP 0.85 Boric Acid NF 0.10 Purified Water USP* To 100 ml *Quantity Sufficient (Q.S.) to provide 100 ml solution.
• the pH of the above buffered saline solution was adjusted so that the pH of the solution was between 7.7 and 7.9.
• the ocular effects of the buffered saline solution containing 0.005 weight/volume percent stabilized chlorine dioxide were evaluated in rabbit eyes in conjunction with Permalens soft contact lenses and multiple topical instillations.
• Test eye lenses were subjected to overnight soaking in the borate buffered saline solution containing 0.005 weight/volume percent stabilized chlorine dioxide followed by direct fit to the eye and 8 hours of wear with topical instillations of the test solution performed at a rate of one drop every one-half hour. Eyes were observed for discomfort and/or gross ocular reactions at lens fit, at each instillation and at lens removal. Slit lamp biomicroscopy was performed following lens removal. Control eyes were subjected to the same regimen using preserved normal saline. No ocular reactions were noted in any rabbit.
• the borate buffered saline solution containing the stabilized chlorine dioxide had the following composition: Ingredients Percent (Weight/Volume) Stabilized Chlorine Dioxide 0.005 Sodium Chloride USP 0.85 Boric Acid NF 0.10 Purified Water USP* To 100 ml *Quantity Sufficient (Q.S.) to provide 100 ml solution.
• the pH of the above buffered saline solution was adjusted so that the pH of the solution was between 7.7 and 7.9.
• the ocular effects of the buffered saline solution containing 0.005 weight/volume percent stabilized chlorine dioxide were evaluated in rabbit eyes following 1 day of multiple topical instillations performed at a rate of one drop every one-half hour for 8 hours. Test eyes were treated with the borate buffered saline solution containing 0.005 weight/volume percent stabilized chlorine dioxide and control eyes were treated with a preserved normal saline solution.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Epidemiology (AREA)
• Pharmacology & Pharmacy (AREA)
• Inorganic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Ophthalmology & Optometry (AREA)
• Engineering & Computer Science (AREA)
• Organic Chemistry (AREA)
• Zoology (AREA)
• Environmental Sciences (AREA)
• Agronomy & Crop Science (AREA)
• Pest Control & Pesticides (AREA)
• Plant Pathology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Dentistry (AREA)
• Wood Science & Technology (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Agricultural Chemicals And Associated Chemicals (AREA)
• Physical Or Chemical Processes And Apparatus (AREA)
• Steroid Compounds (AREA)
• Separation By Low-Temperature Treatments (AREA)
• Audible-Bandwidth Dynamoelectric Transducers Other Than Pickups (AREA)
• Fats And Perfumes (AREA)

Applications Claiming Priority (2)

Publications (2)

Family

ID=23062361

Family Applications (1)

Country Status (20)

Cited By (2)

Families Citing this family (74)

Family Cites Families (37)

• 1989
  • 1989-11-17 IL IL9235189A patent/IL92351A/en not_active IP Right Cessation
  • 1989-11-17 CA CA002003198A patent/CA2003198C/en not_active Expired - Lifetime
  • 1989-11-20 ZA ZA898824A patent/ZA898824B/xx unknown
  • 1989-11-21 NZ NZ231458A patent/NZ231458A/en unknown
  • 1989-11-23 AU AU45499/89A patent/AU621689B2/en not_active Expired
  • 1989-11-24 DK DK593989A patent/DK593989A/da not_active Application Discontinuation
  • 1989-11-27 ES ES89312289T patent/ES2098226T3/es not_active Expired - Lifetime
  • 1989-11-27 DE DE68927631T patent/DE68927631T2/de not_active Expired - Lifetime
  • 1989-11-27 EP EP89312289A patent/EP0371728B1/en not_active Expired - Lifetime
  • 1989-11-27 AT AT89312289T patent/ATE147230T1/de not_active IP Right Cessation
  • 1989-11-28 IE IE378089A patent/IE81090B1/en not_active IP Right Cessation
  • 1989-11-28 FI FI895700A patent/FI895700A0/fi not_active IP Right Cessation
  • 1989-11-28 HU HU896225A patent/HU206455B/hu not_active IP Right Cessation
  • 1989-11-28 NO NO89894740A patent/NO894740L/no unknown
  • 1989-11-29 PT PT92453A patent/PT92453B/pt not_active IP Right Cessation
  • 1989-11-29 KR KR1019890017368A patent/KR0160443B1/ko not_active IP Right Cessation
  • 1989-11-29 CN CN89109005A patent/CN1055874A/zh active Pending
  • 1989-11-29 JP JP1312246A patent/JP2820744B2/ja not_active Expired - Lifetime
• 1991
  • 1991-05-02 US US07/694,640 patent/US5424078A/en not_active Expired - Lifetime
• 1998
  • 1998-05-18 HK HK98104253A patent/HK1005164A1/xx not_active IP Right Cessation

Also Published As

Similar Documents

Legal Events